🚀 VC round data is live in beta, check it out!
Lantheus Holdings Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lantheus Holdings and similar public comparables like RadNet, Diasorin, Sonic Healthcare, Telix Pharmaceuticals and more.
Lantheus Holdings Overview
About Lantheus Holdings
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Founded
2007
HQ
Employees
808
Website
Financials (LTM)
EV
$6B
Lantheus Holdings Financials
Lantheus Holdings reported last 12-month revenue of $2B and EBITDA of $553M.
In the same LTM period, Lantheus Holdings generated $975M in gross profit, $553M in EBITDA, and $397M in net income.
Revenue (LTM)
Lantheus Holdings P&L
In the most recent fiscal year, Lantheus Holdings reported revenue of $2B and EBITDA of $574M.
Lantheus Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $975M | XXX | $942M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $553M | XXX | $574M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $397M | XXX | $416M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | — | — | $210M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lantheus Holdings Stock Performance
Lantheus Holdings has current market cap of $5B, and enterprise value of $6B.
Market Cap Evolution
Lantheus Holdings' stock price is $83.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $5B | -0.1% | XXX | XXX | XXX | $6.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLantheus Holdings Valuation Multiples
Lantheus Holdings trades at 3.8x EV/Revenue multiple, and 10.3x EV/EBITDA.
EV / Revenue (LTM)
Lantheus Holdings Financial Valuation Multiples
As of April 18, 2026, Lantheus Holdings has market cap of $5B and EV of $6B.
Equity research analysts estimate Lantheus Holdings' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lantheus Holdings has a P/E ratio of 13.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBIT | 10.7x | XXX | 10.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | 6.1x | XXX | XXX | XXX |
| P/E | 13.8x | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | 14.8x | XXX | 13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lantheus Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lantheus Holdings Margins & Growth Rates
Lantheus Holdings' revenue in the last 12 month declined by (0%).
Lantheus Holdings' revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.8M for the same period.
Lantheus Holdings' rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lantheus Holdings' rule of X is 20% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Lantheus Holdings Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (0%) | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | (4%) | XXX | (13%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 18% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lantheus Holdings Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lantheus Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| RadNet | XXX | XXX | XXX | XXX | XXX | XXX |
| Diasorin | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Telix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Veracyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lantheus Holdings M&A Activity
Lantheus Holdings acquired XXX companies to date.
Last acquisition by Lantheus Holdings was on XXXXXXXX, XXXXX. Lantheus Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lantheus Holdings
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLantheus Holdings Investment Activity
Lantheus Holdings invested in XXX companies to date.
Lantheus Holdings made its latest investment on XXXXXXXX, XXXXX. Lantheus Holdings invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lantheus Holdings
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lantheus Holdings
| When was Lantheus Holdings founded? | Lantheus Holdings was founded in 2007. |
| Where is Lantheus Holdings headquartered? | Lantheus Holdings is headquartered in United States. |
| How many employees does Lantheus Holdings have? | As of today, Lantheus Holdings has over 808 employees. |
| Who is the CEO of Lantheus Holdings? | Lantheus Holdings' CEO is Mary Anne Heino. |
| Is Lantheus Holdings publicly listed? | Yes, Lantheus Holdings is a public company listed on Nasdaq. |
| What is the stock symbol of Lantheus Holdings? | Lantheus Holdings trades under LNTH ticker. |
| When did Lantheus Holdings go public? | Lantheus Holdings went public in 2015. |
| Who are competitors of Lantheus Holdings? | Lantheus Holdings main competitors are RadNet, Diasorin, Sonic Healthcare, Telix Pharmaceuticals. |
| What is the current market cap of Lantheus Holdings? | Lantheus Holdings' current market cap is $5B. |
| What is the current revenue of Lantheus Holdings? | Lantheus Holdings' last 12 months revenue is $2B. |
| What is the current revenue growth of Lantheus Holdings? | Lantheus Holdings revenue growth (NTM/LTM) is (0%). |
| What is the current EV/Revenue multiple of Lantheus Holdings? | Current revenue multiple of Lantheus Holdings is 3.8x. |
| Is Lantheus Holdings profitable? | Yes, Lantheus Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lantheus Holdings? | Lantheus Holdings' last 12 months EBITDA is $553M. |
| What is Lantheus Holdings' EBITDA margin? | Lantheus Holdings' last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Lantheus Holdings? | Current EBITDA multiple of Lantheus Holdings is 10.3x. |
| What is the current FCF of Lantheus Holdings? | Lantheus Holdings' last 12 months FCF is $387M. |
| What is Lantheus Holdings' FCF margin? | Lantheus Holdings' last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Lantheus Holdings? | Current FCF multiple of Lantheus Holdings is 14.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.